E-mail| Contact Us| Volunteer| Make A Gift| En EspaƱol| Employees

Healthcare Professionals > Featured Links > Oncology Research Protocol Status Report

Oncology Clinical Trials

New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.

The Ann B. Barshinger Cancer Institute participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.

Lancaster General Health is a member of the University of Penn Cancer Network.

Current oncology treatment trials open for participation:

  Study Title



A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy


Familial Breast Cancer Studies

ECOG 2108

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer


Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

RTOG 1005

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost vs. Standard Whole Breast Irradiation plus Sequential Boost for Early-Stage Breast Cancer

SWOG 1007

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (RxPONDER: Rx for Positive Node, Endocrine Responsive Breast Cancer)

WFU 97609

Impact of Genomics and exposures on disparities in breast cancer radiosensitivity


Change in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32


Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)


CALGB 80702


A Phase III Trial of 6 versus 12 treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.


RTOG 0534


A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy

RTOG 1115

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer

SWOG 0931

EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Head and Neck

RTOG 1016


Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer


Bristol -Myers Simplicity


Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study


ECOG 5508


Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.

ECOG 6508

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non Squamous Non Small Cell Lung Cancer After Definitive Chemoradiation

 Updated 1-8-2013.


Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.